echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovative drug development choices: stand alone or flourish?

    Innovative drug development choices: stand alone or flourish?

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Text | leaves

    In 2020, the domestic biomedical capital market will continue to be active.

    On the one hand, the active influx of capital, on the other hand, is affected by external factors such as concentrated procurement, policy changes, and the new crown epidemic.

    However, for Chinese innovative pharmaceutical companies, under the Fast Follow and License-in strategies, which enterprise model can develop better? Does the "king" era that focuses on a drug or a field still exists? Should you choose to bet on a single product that will thrive, or deploy multiple businesses to flourish?

    01 , stood out: residual memories

    01 , stood out: residual memories

    Outstanding one is not a myth, it is engraved in the memory of the times; the future may drift away, but it has also come true.

    The death of the legendary John Martin of Gilead allows us to relive the miracle while cherishing the memory.

    Humira, a legend in the medicine world, has been the world medicine king for nearly 10 years and has independently supported AbbVie's sky.

    Nowadays, it is getting harder and harder to stand out, which is related to the progress of science and technology and the acceleration of iteration.

    However, if the forerunner does not have strong technical barriers, it will inevitably be caught up by Fast Follow, and the cake will be grabbed by the latecomers.

    Do you have the confidence to do a good job?



    With the rapid rise of PD-1/L1, Cinda Bio and Junshi Bio are also actively expanding their business layout.

    It is true that "outstanding" is a short-lived stage for most companies, and will eventually be replaced by a hundred flowers, because companies that don't want to make progress will eventually be eliminated.

    However, not all sowing is reaped.



    For example, although the adverse effects of Enhertu's interstitial pneumonia are worrying, Enhertu does bring significant clinical activity and also disturbs the development of ADC drugs.

    In addition, products with high-tech barriers also have their own barriers.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.